In this issue of Blood, van Eggermond et al demonstrate that Hodgkin lymphoma survivors who develop a second malignancy have increased risk of developing yet a third malignancy.

BACKGROUND Malignancy risk with tumour necrosis factor inhibitor (TNFi) therapy remains unclear. Our primary aim was to assess malignancy risk with TNFi therapy in a cohort of Australian patients with rheumatoid arthritis (RA). We also assessed risk in a biologic-naïve group. METHODS Demographic data of all RA patients enrolled in the Australian Rheumatology Association Database before 25 Oct...

OBJECTIVE The aim of this study was to evaluate the use of risk of malignancy index (RMI) based on a serum CA125 level, ultrasound findings and menopausal status in primary evaluation of patients with adnexal masses in daily clinical practice. METHODS One hundred and fifty one women with adnexal masses were enrolled. Ultrasound characteristics, menopausal status and serum CA125 level were doc...

BACKGROUND The discrimination between benign and malignant adnexal masses is central to decisions regarding clinical management and surgical planning in such patients. PURPOSE OF STUDY To determine if the RMI (RMI 2) can distinguish between benign and malignant adnexal masses. METHODS A prospective cohort study was conducted of 58 women with an adnexal mass referred to a teaching hospital f...

Objective: This study aimed to propose a formula for predicting the biological nature of thyroid nodules, thus helping in clinical decision making and avoiding unnecessary surgery. Patients and methods: Prospective, longitudinal and observational study was conducted on 400 patients submitted to primary thyroid surgery at the Department of Surgery, University of Pisa, Italy, between April 1st an...